Juan C. Sanabria, an analyst from BMO Capital, maintained the Buy rating on Healthpeak Properties. The associated price target is $22.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Juan C. Sanabria has given his Buy rating due to a combination of factors including Healthpeak Properties’ solid performance in the second quarter of 2025. The company’s Adjusted Funds From Operations (Adj-FFO) was in line with market expectations, reflecting a stable financial position. The portfolio’s same-store net operating income (SSNOI) showed a healthy increase, particularly driven by the strength in medical office buildings (MOBs) and continuing care retirement communities (CCRCs).
Despite some challenges in the lab sector, where occupancy rates have declined, the overall guidance for the fiscal year 2025 remains consistent, suggesting confidence in the company’s ongoing operations. The maintained investment levels and general and administrative expenses further indicate a disciplined approach to financial management. These factors combined suggest a positive outlook for Healthpeak Properties, supporting the Buy rating.
In another report released today, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $19.50 price target.
Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of DOC in relation to earlier this year.